China and US agree to extend trade tariff truce, says Li
MONTREAL - Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX), a biopharmaceutical firm with annual revenues of $85.87 million and an impressive 76% gross profit margin, has revealed study results indicating that ibalizumab, used in combination antiretroviral therapy, is effective and safe for heavily treatment-experienced patients with multidrug-resistant HIV. Data from the study were presented at the 2025 Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco. According to InvestingPro analysis, the company appears undervalued, with analysts projecting profitability this year.
The observational registry study, known as PROMISE-US, compared the efficacy of ibalizumab-containing regimens to non-ibalizumab regimens in achieving undetectable levels of HIV RNA. Despite more severe baseline HIV conditions, patients on ibalizumab showed similar rates of viral suppression to controls. With a market capitalization of $69.42 million, Theratechnologies represents a focused player in the specialized pharmaceutical sector.
The interim analysis from the PROMISE-US study included 112 participants, with 42 receiving ibalizumab. After six months, nearly half of the patients in both cohorts achieved undetectable viral loads. At the 12-month mark, the rates were 53% for the control group and 42% for the ibalizumab group. Notably, no infusion reactions or treatment discontinuations due to adverse events were reported among ibalizumab users.
Dr. Smitha Gudipati, an infectious disease specialist at Henry Ford Hospital, highlighted the importance of such treatments for patients with limited options due to resistance to multiple drugs. Christian Marsolais, Ph.D., Senior Vice President and Chief Medical Officer of Theratechnologies, expressed optimism about ibalizumab’s role in modern antiretroviral therapy.
Theratechnologies is focused on the commercialization of innovative therapies and continues to monitor patients in the ongoing PROMISE-US study. The company has cautioned that forward-looking statements in the press release are based on management’s current expectations and involve assumptions, risks, and uncertainties.
This report is based on a press release statement from Theratechnologies. Investors looking for deeper insights can access comprehensive financial analysis and additional ProTips through InvestingPro, which offers exclusive research reports and detailed metrics for over 1,400 US-listed companies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.